

Virus / Prion reduction for Large Plasma-Derived Proteins: Caprylic Acid Treatment and UV-C Irradiation



VirusSure 2nd Virus Safety Workshop, 23-Sep-2022, M. Asper

The manufacturing process of Trimodulin

Highly Confidential results:

Relevant patent information:



VirusSure 2nd Virus Safety Workshop, 23-Sep-2022, M. Asper

The manufacturing process of Trimodulin

Highly Confidential results:

Inactivation of HAV and PPV by [REDACTED] and [REDACTED]

log₁₀ TC [REDACTED]

Relevant patent information

Virus	log ₁₀	qPCR
[REDACTED]	log ₁₀	[REDACTED]
[REDACTED]	log ₁₀	[REDACTED]
[REDACTED]	log ₁₀	[REDACTED]

Greetings from the legal department

Many thanks for your *short* attention!

Virus / Prion reduction for Large Plasma-Derived Proteins: Caprylic Acid Treatment and UV-C Irradiation



Virus / Prion reduction for Large Plasma Derived Proteins

Part 1: Manufacturing process of IgM
(Trimodulin)

Part 2: Caprylic acid treatment
Procedure and case study


Part 3: UV-C treatment
Procedure and case study

Human Plasma derived proteins



Human Plasma donation

- ≈ 92% water
- ≈ 1% salts
- ≈ 7% proteins (> 120 different proteins)



60%	Albumin
4%	$\alpha 1$ -Globulins
8%	$\alpha 2$ -Globulins
12%	$\beta 1+2$ -Globulins
16%	γ -Globulins (IgA, IgD, IgE, IgG, IgM)


Trimodulin

Biotest Trimodulin (IgM Concentrate)

IgM : IgA : IgG ≈ 1 : 1 : 2


Drug application areas of Trimodulin (phase III studies)

- Severe community acquired pneumonia, sCAP
- Severe coronavirus disease 2019 (COVID-19)




Trimodulin – Virus / Prion Safety

Prion Protein (PrP ^{Sc}):	35 KDa
IgG:	150 KDa
IgA:	160 KDa
IgM:	960 KDa (≈29-35 nm)



<https://viralzone.expasy.org/5216>

Manufacturing process of Trimodulin



Virus / Prion reduction for Large Plasma Derived Proteins



Part 1: Manufacturing process of IgM
(Trimodulin)

Part 2: Caprylic acid treatment
Procedure and case study

Part 3: UV-C treatment
Procedure and case study

Caprylic Acid

Caprylic Acid
 $\text{CH}_3(\text{CH}_2)_6\text{CO}_2\text{H}$




Main contributor to
virus inactivation

pK_a 4.89

→ Virus inactivation: pH, temperature and time dependend


Caprylic Acid treatment



13

23-September-2022, M. Asper

Caprylic Acid treatment




Different mechanisms for enveloped / non-enveloped viruses & Prions

- Enveloped Virus *inactivation* by Caprylic Acid
- non-enveloped Virus / Prion *removal* by precipitation with impurities

14

23-September-2022, M. Asper

Case study: Caprylic Acid treatment





15

23-September-2022, M. Asper

Biotest
From Nature for Life

Case Study: Caprylic Acid treatment virus inactivation




(100 mM CA)

16

23-September-2022, M. Asper

Biotest
From Nature for Life

Case Study: Caprylic Acid treatment virus inactivation



Inactivation of enveloped viruses:
Very quick and very effective

Case Study: Caprylic Acid treatment Virus / Prion removal

Virus	Infectivity Assay	qPCR
HAV	> 3.7 log10	1.9 log10
HEV	---	> 4.8 log10
PPV	1.7 log10	---
B19V	---	2.5 log10

Prion	In-vitro	In-vivo
PrP ^{Sc} (263K)	> 3.9 log10	6.0

Virus / Prion reduction for Large Plasma Derived Proteins

Part 1: Manufacturing process of IgM
(Trimodulin)


Part 2: Caprylic acid treatment
Procedure and case study

Part 3: UV-C treatment
Procedure and case study



UV-adsorption spectra of protein and nucleic acid

- Adsorption maxima:
proteins at ≈ 280 nm,
DNA/RNA at ≈ 260 nm

→ UV-C irradiation at 254 nm is preferentially absorbed by nucleic acids over proteins



UV-adsorption spectra of Trimodulin



S. Luefl, et al., 2022, submitted

UV-C action on nucleic acids

DNA/RNA damage





Image: Wikimedia Commons
Public Domain, author garriet41

- Prominent mechanism: direct hits of purine/pyrimidine bases
- UV-C irradiation leads to covalent bonds between neighbouring Pyrimidine nucleotides

➔ Formation of cyclobutane „rings“:



UV-C equipment

What is needed?

1. UV-C lamp

generating UV-C irradiation

2. UV-C „reactor“

vessel/container where
process feed is irradiated

23


23-September-2022, M. Asper

UV-C treatment

• Limited UV-C penetration in protein solutions

- Exponential decay of UV intensity (W/m^2)
- E.g. at $\text{OD}_{254\text{nm}} = 5.0$
and depth = 2 mm:
loss of 90% of UV intensity

$\text{OD}_{254\text{nm}} = 5.0$ (protein concentration: approx. 9.5 g/l)



24

23-September-2022, M. Asper

Homogenous mixing

homogenous mixing = lower UV-C dose required




less protein damages + more virus inactivation

UV-C UVivatec® technology

Dean Vortices

UV module cross-section (UVivatec technology)



S. Luelf, et al., 2022, submitted

Dean Vortices

Primary Flow





Figure modified after Sudarsan and Ugaz (2006)

Fluid dynamics simulation



Lab scale versus process scale unit

lab scale unit



	lab scale	process scale
Volume of module	24 mL	140 mL
Optical path length	2 mm	3.5 mm
Flow rate	6 – 20 L/h	30 – 120 L/h
Feasible for protein conc.	3-19 g protein per L	6-19 g protein per L



process scale unit




Case study: UV-C irradiation for Trimodulin

UV-C irradiation of Trimodulin:


- OD_{254nm} (approximate): >3 (= protein concentration of > 6 g/L)
- UV-C dose: 100 - 200 J/m²

Case study: PPV in lab / process scale unit



PPV inactivation:
very effective

Case study: HAV in lab / process scale unit



HAV inactivation:
incomplete inactivation,
but effective at ≈ 200 J/m²
(below IgM target UV-C
dose)















Case study: UV-C treatment

Virus	lab scale [log ₁₀]	process scale [log ₁₀]
BVDV	2.99	---
HIV	0.63	---
PRV	3.76	---
HAV	4.53	4.28
PPV	6.96	6.60

→ Equivalence with process scale unit could be demonstrated

Standard conditions: 200 J/m²
Mean values of different experimental runs

Summary

Virus	Envelope	Caprylic acid treatment	UV-C Virus inactivation
PPV	No		
B19V	No		Not performed
HAV	No	 	
HEV	No		Not performed
BVDV	Yes		 
HIV	Yes		
PRV	Yes		



Virusure Team Biotest Pathogen Safety Group Biotest Development Group



Gerhard Poelsler
Sebastian Luelf

Achim Hannappel
Fabian Jung

marcel.asper@biotest.com

